Besremi: Efficacy and Safety in Different Age Groups

[Manouche]

« In summary, after 24 months ropeginterferon induced higher hematological and molecular response rates and higher maintenance of response than HU in PV patients in the age groups < 60 years and ≥60 years, with the latter consisting of a majority of patients between 60 and 70 years of age and only a small number of patients aged over 75 years. In contrast to previous observations with other pegylated IFNs, ropeginterferon was efficacious and well tolerated even in the elderly cohort. Moreover, the safety analysis in patients ≥60 years showed a positive trend regarding fewer and less serious treatment-related AEs compared to HU »

journals.lww.com/hemasphere...

[charl17]

My mpn specialist wants to switch me from Pegasys to Besremi as soon as the FDA approves for the US. I hope we can start this in March. I am doing well on Pegasys and expect to do even better on Besremi.

[MPort]

Thank you for posting this info. So it compares efficacy of new interferon to Hu. I wonder how it does when compared to Pegasys?

[Manouche in reply to MPort]

That’s a good question. Theorically, there’s not much difference between Besremi and Pegasys in term of efficacy. However, haems are looking at reducing toxicity and improving tolerability of the medication. Interferon can functionally cure 8 to 20% of patients. Hopefully less toxicity would allow to functionally cure over 50% of MPN patients.